Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-year open-label extension study of canakinumab in active rheumatoid arthritis
2008-005320-81Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in rheumatoid arthritis (RA), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of canakinumab. Started Sep 2008; status: terminated.
02
Drugs
canakinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-005320-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005320-81.